Bold Therapeutics to Unveil Novel Metallotherapeutics at 2026 Conference

Bold Therapeutics Set to Make Waves in Metallotherapeutics at 2026 Conference

Bold Therapeutics, an emerging biopharmaceutical company focused on innovative metallotherapeutics, is gearing up for participation in the highly-regarded 2026 Metals in Medicine Gordon Research Conference, to be held in Andover, New Hampshire this week. The event brings together leaders and experts in the field to explore advancements in metal-based medicines.

An important highlight at this conference will be Dr. Shane Harrypersad from Bold Therapeutics, who is scheduled to lead a panel discussion on "Opportunities and Challenges for the Advancement of Metal-Based Drugs in the Clinic." This discussion aims to illuminate the practical challenges and exciting opportunities in transitioning metal-based therapeutics from the laboratory to clinical settings.

Dr. Maria Contel, the Co-Chair of the conference and a professor at Brooklyn College, emphasized the importance of Bold's participation, stating that the insights provided by Dr. Harrypersad could significantly benefit all attendees. Beyond knowledge-sharing, this role grants Bold Therapeutics valuable exposure and the chance to forge collaborations with notable scientists, potentially influencing future efforts within the metals-in-medicine sphere.

This year's focus revolves around creating momentum for targeted metal-based therapies and diagnostics. Reflecting on Bold's position, Dr. Harrypersad expressed optimism, stating, "As the leading clinical-stage Ruthenium-III based therapy, we aim to propel the next era of innovative metal-based medical treatments."

As Bold Therapeutics continues to expand its metallotherapeutics portfolio, excitement surrounds the progress of BOLD-100, its most advanced clinical candidate. BOLD-100 is currently undergoing a global Phase 2 randomized controlled trial across multiple locations, including sites in Canada, the European Union, and South Korea. This trial investigates BOLD-100's anticancer properties, while also integrating quality of life assessments that focus on its neuroprotective capabilities.

Notably, BOLD-100 has shown promise in protecting patients from chemotherapy-induced peripheral neuropathy, which could offer significant therapeutic advantages for those battling gastrointestinal cancers. These developments are set to transform the clinical landscape and improve the quality of life for patients.

For those looking to explore further, detailed information can be found on ClinicalTrials.gov (NCT04421820).

As Bold Therapeutics prepares for this pivotal conference, the company invites potential investors and interested parties to find more information at Bold Therapeutics' website. For direct inquiries, please contact Jim Pankovich, Executive Vice President, at (604) 262-9899 or via email.

The participation in this prestigious conference highlights the eagerness and determination of Bold Therapeutics to lead in the forefront of metallotherapeutic innovations, laying the foundation for a new wave of targeted cancer treatments.